330889 RESULTS
THERAPEUTICS 1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate Pfizer Shionogi Pharma Cognex™ Small Molecule Cholinergic System Tacrine is a reversible acetylcholinesterase inhibitor. Originally developed by Warner-Lambert Co., tacrine was the first such
THERAPEUTICS 1-{3-[2-(1-benzothiophen-5-yl)ethoxy] propyl}-3-azetidinol maleate Toyama Chemical Co., Ltd. T-817 MA, T 817 Small Molecule Other Unknown Phase 1 development for T-817MA began in 2005. From 2008 to 2011, a multicenter Phase 2a trial in North America compa
THERAPEUTICS Aventis Pharmaceuticals, Inc. (was Hoechst) MD 26479 Small Molecule Other Neurotransmitters Suritozole is an inverse agonist at the GABA(A) receptor (Miller et al., 1992). GABA(A) receptor activity affects cholinergic function in the hippocampus and cereb
THERAPEUTICS spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one Sonexa Therapeutics, Inc. ZSET1446 Small Molecule Unknown Two Phase 2 trials in Alzheimer's disease, conducted at multiple sites in the United States and Canada, have been completed. One compared thre
THERAPEUTICS Merck Zocor® Lipex® Lipovas® Denan® Small Molecule Cholesterol Widespread clinical interest in statins for the treatment of Alzheimer's began around 2002, when a clinical trial in Germany reported a signal that simvastatin treatment was able to lower
THERAPEUTICS (3-Aminopropyl)butylphosphinic acid Novartis Pharmaceuticals Corporation Saegis Pharmaceuticals, Inc. CGP-36742 DVD-742 Small Molecule Other Neurotransmitters SGS742 is a GABA(B) receptor antagonist. Alzheimer's Disease Discontinued Breaking News htt
THERAPEUTICS Sabcomeline Memric Small Molecule Other Neurotransmitters SB 202026 is a selective muscarinic M1 receptor partial agonist. Alzheimer's Disease Discontinued Breaking News http://www.alzforum.org/drg/drc/detail.asp?id=80
THERAPEUTICS R58735 Small Molecule Unknown Sabeluzole has been reported to reduce glutatmate toxicity in part by reducing NMDA-induced inward current (Van der Valk et al., 1993). It also has been shown to affect cytoskeletal stability (Geerts et al., 1996) and tau exp
THERAPEUTICS 5-[[4-[2-(methyl-pyridin-2-yl-amino)ethoxy]phenyl]methyl]thiazolidine-2,4-dione, AVANDIA® GlaxoSmithKline (GSK) Rosiglitazone maleate Avandia Small Molecule Other A dozen clinical studies have evaluated rosiglitazone in AD. Starting in 1999, a pilot study
THERAPEUTICS Merck Vioxx™ Small Molecule Inflammation Three clinical trials of rofecoxib in Alzheimer's disease have been conducted. In 2000 and 2001, the Alzheimer's Disease Study Group conducted a 40-center trial that compared one year of treatment with 25
THERAPEUTICS N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide hydrochloride RO5313534 MEM 3454 Small Molecule Cholinergic System Roche licensed this therapeutic from Memory Pharmaceuticals Corp. In 2006, Memory Pharmaceuticals had announced positive pre
THERAPEUTICS trans-3,4',5-trihydroxystilbene Small Molecule Supplement, Dietary Other Between 2008 and 2010, a Phase 3 trial at the Veterans Affairs Medical Center in the Bronx, New York, evaluated a one-year course of treatment with a liquid formulation of resve
THERAPEUTICS 7-isopropyl-6-oxo-5(3-piperidin-1-yl-propylcarbamoyl)-6,7-dihydro-thieno[2,3-b]pyridine-4-olate Epix Pharmaceuticals Potassium salt Small Molecule Other 5-HT4 receptor agonists augment neuronal acetylcholine release (Ansanay et al., 1995; Torres et al., 1
RESEARCH NEWS 2013-04-12 Research News Could cranking up a cellular waste removal system help rid the brain of misfolded α-synuclein, the principle component of Lewy bodies found in neurodegenerative disorders such as Parkinson’s disease (PD)? Perhaps not, suggest researchers led
PAPER Petit GH, Berkovich E, Hickery M, Kallunki P, Fog K, Fitzer-Attas C, Brundin P
No filters selected
